Health Care • Biotechnology: Pharmaceutical Preparations
$6.22 ▼ -0.06
(-0.95%)
MKT CAP: $503.2M • VOL: 3.84M
52W L $5 52W H $18
ROARABLE / RQD
D • 46/100
PIOTROSKI
4 / 9
PHAT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $175.1M | $55.3M | $682.0K |
| YoY Revenue Growth % | +216.9% | +8001.5% | — |
| Gross Profit | $152.5M | $47.3M | — |
| Gross Margin % | 87.1% | 85.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$160.0M | -$277.5M | -$167.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$221.3K | -$334.3K | -$201.6K |
| EBITDA (Normalized) | -$159.8M | -$277.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$166.8M | -$266.8M | -$137.6M |
| Capital Expenditures (CapEx) | $229.0K | $135.0K | — |
| Free Cash Flow (FCF) | -$167.0M | -$266.9M | -$137.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $130.0M | $297.3M | — |
| Total Debt (Short + Long Term) | $209.1M | $201.4M | — |
| Total Stockholders' Equity | -$438.2M | -$253.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PHAT.